La cadena de opciones muestra datos clave de las opciones de acciones de PS International Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para PS International Group..

PS International Group (NASDAQ:PSIG) Bolsa, Cadena de Opciones

PS International Group

PS International Group Ltd is a freight forwarding service provider in Hong Kong with networks across the globe. It provides air and ocean export and import freight forwarding services with optional ancillary logistics-related services such as cargo pick up, cargo handling at ports, and local transportation and warehousing-related services such as repackaging, labeling, palletization, preparation of shipping documentation, arrangement of customs clearance and warehousing to meet the requirement of customers.

PS International Group Ltd. - Ordinary Shares

PS International Group Ltd

News

Guidance

TSLA

Tesla Says Will Revisit FY25 Guidance In Q2 Update; Says It Has Sufficient Liquidity To Fund Product Roadmap, Long-Term Capacity Expansion Plans And Other Expenses, Says Plans For New Vehicles, Including More Affordable Models, Remain On Track For Start Of Production In The First Half Of 2025

WIIM

PEGA

Pegasystems shares are trading higher after the company reported better-than-expeted Q1 financial results.

ENPH

Enphase Energy shares are trading lower after the company reported worse-than-expected Q1 financial results.

Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2.74 by 13.5 percent. This is a 21.48 percent increase over earnings of $2.56 per share from the same period last year. The company reported quarterly sales of $262.87 million which beat the analyst consensus estimate of $259.11 million by 1.45 percent. This is a 6.32 percent increase over sales of $247.25 million the same period last year.

Earnings

Earnings Beats

CASH

Pathward Financial Q2 EPS $3.11 Beats $2.74 Estimate, Sales $262.87M Beat $259.11M Estimate

Dear Fellow Shareholders,
Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Longeveron's founding mission - developing cutting-edge cellular therapy research to impact patients' lives for the better by addressing unmet medical needs. We have come a long way pursuing that mission and now have clarity on the pathway to our first potential Biological License Application (BLA) submission.
Today, I am excited to update you on our overall strategy, progress, and key priorities and goals for 2025.
Strategic Overview and 2024 Progress: Over the past decade, stem cell therapy has seen remarkable strides, transforming from a promising field into one delivering tangible clinical outcomes. We've seen the solidification of cell therapy's role in regenerative medicine and its potential to treat a wide range of conditions, signaling an exciting future for both scientific innovation and patient care.
Longeveron has been at the forefront of this evolution in medicine. Our lead investigational product is laromestrocel (Lomecel-B&#x2122;), a stem cell therapy derived from culture-expanded mesenchymal stem cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The number of functional MSCs in the body declines as we age, which has driven interest in their use for aging-related conditions. Their unique properties — including the ability to reduce inflammation, promote tissue repair and regeneration, modulate immune responses, and improve vascularization — also support their application in some rare cardiovascular diseases/conditions with high unmet medical need. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions.
A decade ago, our stem cell therapy vision was an academic idea. Today, laromestrocel represents a pipeline in a product opportunity that has delivered positive results from multiple clinical trials: Phase 1 &amp; 2 in Alzheimer's disease, Phase 1 &amp; 2 in Aging-related Frailty, Phase 1 in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease. We are currently conducting a pivotal Phase 2b clinical trial for HLHS. Our development programs for these 3 initial indications address market opportunities of what we estimate to be approximately ~$5+ billion, ~$4+ billion and up to ~$1 billion, respectively. Earlier this year, the World Health Organization's International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" as the non-proprietary name for Lomecel-B&#x2122; — a key milestone in the development and future commercialization of our stem cell therapy.
As we did this past year, in 2025, we will continue focusing our efforts on two of our most promising programs: HLHS and Alzheimer's disease.
Hypoplastic Left Heart Syndrome (HLHS):
HLHS is a rare pediatric disease in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. Because the left ventricle is the chamber that normally pumps blood to the body, infants born with this condition have a profound reduction in blood flow and thus cannot get the normal supply of oxygen to their organs. In order for the children to survive, they must undergo a complicated, three-stage heart reconstruction surgery over the course of the first 5 years of their lives. Despite this surgical reconstruction, only 50% of the affected children survive to age 15 without heart transplantation.
Our program is designed to boost/improve the heart function in these children with the goal of potentially enhancing their survival. In our Phase I clinical trial (ELPIS I) evaluating laromestrocel in 4-month-old infants with HLHS, we observed 100% transplant-free survival up to five years following treatment. This contrasts with an approximately 20% mortality rate observed in historical control data. Five-year post-treatment long-term survival data from the ELPIS I Phase 1 clinical trial was presented at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting in October 2024.
We are currently nearing completion of enrollment for our Phase 2b study, ELPIS II, which is evaluating laromestrocel as a potential adjunct treatment to the standard of care for HLHS. ELPIS II has achieved nearly 95% enrollment, and we expect to complete enrollment in the second quarter of this year.
In September 2024, we completed a Type C meeting with the U.S. FDA regarding our HLHS development program and the pathway toward a potential BLA submission. We reached foundational alignment on the primary endpoint and secondary endpoints for the ELPIS II trial. The FDA confirmed that, contingent on positive results, ELPIS II may be considered a pivotal trial and potentially acceptable for BLA submission seeking full traditional approval. With this regulatory clarity, we are now focused on BLA preparedness and enabling activities for the HLHS program. Notably, because this program has received Rare Pediatric Disease Designation, we may be eligible to receive a Priority Review Voucher (PRV) if our BLA is approved. We may use the PRV internally or sell to a third party. Historically, PRVs have commanded values exceeding $100 million.
Alzheimer's Disease:
The laromestrocel Alzheimer's disease (AD) program continues to garner important recognition and support. In 2024, data from the CLEAR MIND Phase 2a clinical trial evaluating laromestrocel in mild Alzheimer's disease were presented as a featured research oral presentation at the 2024 Alzheimer's Association International Conference held at the end of July and as a late breaking poster presentation at the 17th edition of the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in October. We are very excited about the trial's positive results. The trial met its primary objective of demonstrating safety, with laromestrocel being well-tolerated. In addition, we observed encouraging trends suggesting a potential slowing or prevention of disease progression in patients treated with laromestrocel compared to placebo.
This program has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, providing us with the opportunity for enhanced and frequent communication with the FDA to facilitate the development and review process. In March of this year, results from the trial were <a href="https://www.globenewswire.com/Tracker?data=q5z76BEDJ6-_BNlI7zxiW7bj7HH_JA6z2l_-sTbO61K_qKYtMQAMaF9FDMVXrEj3T_9nYmWCk-Lq0zdwrX4bx2qd5ntW3sf1N8Ytp1j1BkoTux4GUbqWzdOydRL9flts">published</a> in Nature Medicine.
Also in March of this year, we held a Type B meeting with the FDA to discuss the regulatory pathway for a potential BLA for laromestrocel in mild Alzheimer's disease. We reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial. To support an accelerated path to potential approval, the FDA agreed to consider a BLA submission based on positive interim results from this planned single study.
With this regulatory clarity in hand, we are focused on seeking partnership opportunities and/or non-dilutive funding for the Alzheimer's disease program.
Our Core Business Objectives: Our strategic plan is built on the strength of the science underlying our stem cell therapy laromestrocel. For 2025, we are focused on four key objectives:
<ol>
<li>Advance HLHS Program as the Main Near-Term Value Driver:
<ul>
<li>Pivotal Phase 2 clinical trial (ELPIS II) is nearing enrollment completion.</li>
<li>Regulatory pathway clarified with U.S. FDA.</li>
<li>Potential to initiate rolling BLA submission in 2026.</li>
<li>Potential to receive a Rare Pediatric Disease priority review voucher associated with HLHS upon BLA approval which could have significant monetary value and further enhance our product's value proposition upon approval.</li>
</ul>
</li>
<li>HLHS BLA and Commercialization Readiness:
<ul>
<li>Successful meeting with FDA confirmed ELPIS II could be pivotal.</li>
<li>2025 will see significant focus on organizational readiness for potential BLA filing for HLHS in 2026. Our goal is to accomplish BLA readiness this year ahead of data readout to potentially shorten the timeline to BLA submission.</li>
<li>Emphasis on Chemistry, Manufacturing, and Controls (CMC) preparedness.</li>
<li>Hired industry veteran Chief Technology Officer to support BLA preparedness.</li>
<li>We are committed to helping HLHS patients worldwide. In 2025, we intend to take initial steps connecting with non-U.S. regulatory bodies, including EMA (European Union), MHRA (United Kingdom), PMDA (Japan) and HealthCanada.</li>
<li>Recognizing substantial revenue potential from worldwide commercialization, we anticipate capitalizing on recent rare disease pricing trends and the unique aspects of our treatment.</li>
</ul>
</li>
<li>Strategic Collaborations for Alzheimer's Disease:
<ul>
<li>We believe our Alzheimer's disease program holds immense potential. Due to the large size of the affected population, it involves larger-scale studies and commercialization requirements. This scale of development effort necessitates significant investment, prompting our focus on potential strategic partnerships with biotech/pharmaceutical companies and/or non-dilutive funding sources.</li>
<li>We believe the clarity on the pathway to potential BLA submission and the need for only a single pivotal clinical trial enhance the attractiveness and economic benefits of the program to potential partners.</li>
</ul>
</li>
<li>Efficient Resource Management and Capital Allocation:
<ul>
<li>We strive to be prudent stewards of shareholder capital and focus allocating it to the organization's top priorities to effectuate optimal resource utilization and alignment with strategic objectives.</li>
<li>We prudently manage expenses. In 2024, we reduced total operating expenses 13% while continuing to effectively advance our development programs.</li>
</ul>
</li>
</ol>
Financial Position and Capital Strategy: Longeveron is working diligently to effectively advance our development programs while managing expenses and our capital. We will need additional capital to achieve our business strategy and objectives.
We indicated in our recently filed Annual Report on Form 10K that we anticipated our existing cash and cash equivalents would fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. However, as we also indicated, as a result of our successful Type C meeting with the FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up BLA enabling activities to prepare for a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. We expect our operating expenses and capital expenditure requirements to accelerate this year as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness. We intend to seek additional financing and non-dilutive funding options to support these activities, and additional non-dilutive funding and/or strategic partners to support the AD development program. We anticipate that our current cash projections may be impacted by these ramped up activities and any financing transactions we enter into.
2025 Goals and Priorities Our goals for 2025 center on efficient, effective execution of our strategic plan with an emphasis on three primary operational goals:
<ol>
<li>ELPIS II Completion: We anticipate completion of ELPIS II enrollment in the second quarter of 2025. We will then focus on supporting our investigative sites through completion of the 12-month primary endpoint follow-up period and preparation for data collection and analysis at the end of the study.</li>
<li>HLHS BLA Preparedness: We intend to accomplish the majority of BLA readiness in 2025 to support a potentially shortened time frame from clinical trial readout to BLA submission.</li>
<li>Alzheimer's Disease Program Partnering: We plan to leverage the strength of our Phase 2 data and clarity on the clinical pathway to a potential BLA for AD to engage with potential funding/commercialization partners. &nbsp;</li>
</ol>
Outlook Longeveron has made tremendous progress in two important stem cell development programs over the past 12 months, successfully delivering on our strategic plan. We are now approaching multiple potentially transformational milestones over the next 12 months including completion of enrollment in our pivotal Phase 2b clinical trial in HLHS which may establish the timeline for a potential BLA submission for HLHS, and potential partnering for the Alzheimer's disease program. Our team's expertise and industry experience enable the organization to accomplish so much with a small team and few resources. Generating several positive initial results across five clinical trials in three indications, continues to position Longeveron as a leader in stem cell therapy research and, potentially, commercialization of cellular therapeutics.
We believe Longeveron's demonstrated track record of successful clinical execution, strength of data generated to date and the potential size of addressable markets provide for a compelling investment opportunity.
We deeply appreciate the support of our stakeholders and look forward to continued collaboration and progress in the future.
Sincerely, Wa'el Hashad CEO, Longeveron

LGVN

Longeveron Issues Letter To Shareholders

Jefferies analyst Matthew Murphy maintains Triple Flag Precious (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#NYSE">TFPM</a>) with a Buy and raises the price target from $24 to $26.

Price Target

Analyst Ratings

TFPM

Jefferies Maintains Buy on Triple Flag Precious, Raises Price Target to $26

Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) reported quarterly earnings of $0.68 per share which missed the analyst consensus estimate of $0.70 by 2.86 percent. This is a 94.29 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $356.10 million which missed the analyst consensus estimate of $361.43 million by 1.48 percent. This is a 35.22 percent increase over sales of $263.34 million the same period last year.

Earnings Misses

Enphase Energy Q1 Adj. EPS $0.68 Misses $0.70 Estimate, Sales $356.10M Miss $361.43M Estimate

SAP shares are trading higher after the company reported better-than-expected Q1 EPS results.

Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) shares closed higher <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">on Tuesday.</a>
The firm announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44926580/warner-music-group-partners-with-entrepreneurial-powerhouse-anjula-acharia" rel="noreferrer noopener">new joint venture</a> with entrepreneur Anjula Acharia<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44926580/warner-music-group-partners-with-entrepreneurial-powerhouse-anjula-acharia" rel="noreferrer noopener">.</a>
The partnership marks the debut of 5 Junction, a new label under Warner&#8217;s umbrella aimed at uplifting artists of South Asian descent based in the United States and spotlighting existing Warner talent from South Asia and its global diaspora.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/04/44926902/imf-slashes-us-growth-outlook-as-trump-tariffs-bite-raises-recession-odds-to-40" target="_blank" rel="noreferrer noopener">IMF Slashes US Growth Outlook As Trump Tariffs Bite, Raises Recession Odds To 40%</a>
The company said its latest initiative will closely collaborate with Los Angeles-based Warner Records, led by Tom Corson and Aaron Bay-Schuck.
Anjula Acharia, the founder of 5 Junction, brings years of cross-cultural expertise to the new venture. She emphasized that showcasing South Asian creativity isn&#8217;t about chasing trends but about acknowledging cultural truths and global influence.
Acharia, known for launching Priyanka Chopra Jonas&#8217; Hollywood career and bridging gaps between global talent and opportunity, aims to amplify the reach of underrepresented voices in the music industry through 5 Junction.
Robert Kyncl, CEO of Warner Music Group, praised Acharia&#8217;s extensive network and entrepreneurial spirit, calling her a &#8220;creative and entrepreneurial dynamo.&#8221;
He noted the company&#8217;s early recognition of South Asian music&#8217;s potential and said this new venture is positioned to strengthen the cultural and commercial bridge between South Asia and North America. Corson and Bay-Schuck also expressed confidence in the label&#8217;s ability to scale South Asian music&#8217;s influence in the U.S. market.
5 Junction will also align with Warner Music India, which has rapidly expanded its reach across the region.
Additionally, 5 Junction will collaborate with 91 North Records, a Toronto-based joint venture between Warner Music India and Warner Music Canada, focused on blending South Asian music with Canadian influences.
Acharia&#8217;s track record connects Western superstars like Lady Gaga and Britney Spears to South Asian audiences.
She&#8217;s also invested in major startups like Bumble and ClassPass, consistently advocating for inclusive representation at the intersection of technology, culture, and celebrity.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, WMG stock has lost over 14% in the past year. On Monday, Morgan Stanley analyst Benjamin Swinburne downgraded Warner Music from Overweight to Equal-Weight, <a target="_blank" href="https://www.benzinga.com/quote/WMG/analyst-ratings" rel="noreferrer noopener">lowering the price forecast from&nbsp;$37&nbsp;to&nbsp;$32.</a>
Investors can gain exposure to the stock via&nbsp;MUSQ Global Music Industry Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSQ#NYSE">MUSQ</a>).
Price Action: WMG shares closed higher by 1.15% to $28.04 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43533373" target="_blank" rel="noreferrer noopener">Warner Music Sees Lower Profit Margins, Signs Multi-Year Spotify Deal</a></li>
</ul>

Equities

Markets

Movers

Tech

General

MUSQ

What's Going On With Warner Music Group Stock On Tuesday?

Tesla Says Q1 Revenue Was Negatively Impacted By Lower Deliveries, Reduced ASP And $0.3B FX Impact, But Positively Impacted By By Energy And Credit Growth

Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.03 by 15.53 percent. This is a 15.53 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $262.79 million which beat the analyst consensus estimate of $256.60 million by 2.41 percent. This is a 3.24 percent increase over sales of $254.55 million the same period last year.

MANH

Manhattan Associates Q1 Adj. EPS $1.19 Beats $1.03 Estimate, Sales $262.79M Beat $256.60M Estimate

ISRG

Intuitive Surgical shares are trading lower. The company reported Q1 financial results.

OKLO

Oklo shares are trading lower following a report suggesting Sam Altman is stepping down as the company's board chair.

JPMorgan analyst Christopher Horvers noted improved year-over-year store performance at Lowe&#8217;s Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) and strong seasonal traffic at Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) <a href="https://www.benzinga.com/quote/HD/analyst-ratings" target="_blank" rel="noreferrer noopener">during a recent visit to Philadelphia.</a>
Horvers observed that while Home Depot continued to lead in overall traffic and sales volume—particularly at its King of Prussia location—Lowe&#8217;s stores showed meaningful year-over-year improvement, taking the next two top-performing <a target="_blank" href="https://www.benzinga.com/quote/LOW/analyst-ratings" rel="noreferrer noopener">spots in the Philadelphia area.</a>
His recent store checks revealed stronger lawn and garden traffic at most locations visited, likely boosted by favorable weather and the three-day weekend during Good Friday, with customer activity significantly higher than last year and last week&#8217;s visits in New Jersey.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44920573/ceos-of-walmart-target-home-depot-meet-trump-to-push-back-on-tariffs-impacting-consumer-prices" rel="noreferrer noopener">Trump Meets With Walmart, Home Depot And Target CEOs To Discuss Tariff Impacting Consumer Prices</a>
However, activity among professional customers appeared weaker, with fewer trucks in Pro parking areas and a lower number of Pros at service desks compared to last year.
While &#8220;warmer&#8221; weather is forecasted for the Northeast, it could lift DIY demand in the near term, but &#8220;unsettled&#8221; weather patterns over the next two weeks could still pose headwinds.
Horvers writes that Numerator data suggests Lowe&#8217;s has faced a greater weather-related drag on spring sales compared to Home Depot.
While both retailers saw a slow start to the season, Home Depot appears to be recovering more quickly.
Outdoor DIY sales at HD rose roughly 4% overall and surged 21% in the week ending April 6, whereas Lowe&#8217;s sales remained down about 10% for the quarter to date—though that&#8217;s an improvement from the earlier 15% drop—and were roughly flat during the same week.
Encouragingly, seasonal sales have started to pick up for both companies since late March, with Home Depot maintaining a stronger rebound, particularly outside the Southern U.S., where gains have been more muted, the analyst further notes.
Price Action: LOW shares traded higher by 2.9% to $219.07 on Tuesday, while HD shares were up 2.1% to $354.43.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44930495/wall-street-rebounds-ahead-of-tesla-earnings-dow-adds-1000-points-bitcoin-hits-91000-whats-driving-markets-tuesday" target="_blank" rel="noreferrer noopener">Wall Street Rebounds Ahead Of Tesla Earnings, Dow Adds 1,000 Points, Bitcoin Hits $91,000: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Trading Ideas

Weather Hits Lowe's Harder Than Home Depot As Spring Traffic Heats Up: Analyst

Enphase Energy Q1 Adj EPS $0.68 Misses $0.70 Estimate, Sales $356.10M Miss $361.43M Estimate

Outlook 2025
Financial Outlook 2025
While the prevailing dynamic environment implies elevated levels of uncertainty and reduced visibility, SAP currently continues to expect:
<ul>
<li>€21.6 – 21.9 billion cloud revenue at constant currencies (2024: €17.14 billion), up 26% to 28% at constant currencies.</li>
<li>€33.1 – 33.6 billion cloud and software revenue at constant currencies (2024: €29.83 billion), up 11% to 13% at constant currencies.</li>
<li>€10.3 – 10.6 billion non-IFRS operating profit at constant currencies (2024: €8.15 billion), up 26% to 30% at constant currencies.</li>
<li>Approximately €8.0 billion free cash flow at actual currencies (2024: €4.22 billion)</li>
<li>An effective tax rate (non-IFRS) of approximately 32% (2024: 32.3%)2.</li>
</ul>
The company also continues to expect current cloud backlog growth at constant currencies to slightly decelerate in 2025.
While SAP's 2025 financial outlook for the income statement parameters is at constant currencies (including an average exchange rate of 1.08 USD per EUR), actual currency reported figures are expected to be impacted by currency exchange rate fluctuations as the company progresses through the year, as reflected in the table below.
Currency Impact Assuming March 31, 2025. Rates Apply for 2025
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">In percentage points</td>
<td colspan="1" rowspan="1">Q2 2025</td>
<td colspan="1" rowspan="1">FY 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cloud revenue growth</td>
<td colspan="1" rowspan="1">-1.0pp</td>
<td colspan="1" rowspan="1">-2.0pp</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cloud and software revenue growth</td>
<td colspan="1" rowspan="1">-1.0pp</td>
<td colspan="1" rowspan="1">-0.5pp</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating profit growth (non-IFRS)</td>
<td colspan="1" rowspan="1">0.0pp</td>
<td colspan="1" rowspan="1">-1.0pp</td>
</tr>
</tbody>
</table>
</figure>
This includes an exchange rate of 1.08 USD per EUR.
 &nbsp;

SAP Sees FY25 Cloud Revenue €21.6 Billion – €21.9 Billion; Cloud And Software Revenue €33.1 Billion – €33.6 Billion, At Constant Currencies

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) reported quarterly earnings of $2.08 per share which missed the analyst consensus estimate of $2.15 by 3.26 percent. This is a 0.48 percent increase over earnings of $2.07 per share from the same period last year.

EWBC

East West Bancorp Q2 Adj $2.08 Misses $2.15 Estimate

<a href="https://www.cnbc.com/2025/04/22/sam-altman-steps-down-as-oklo-chair-freeing-nuclear-company-up-to-work-with-more-ai-companies.html?qsearchterm=oklo">https://www.cnbc.com/2025/04/22/sam-altman-steps-down-as-oklo-chair-freeing-nuclear-company-up-to-work-with-more-ai-companies.html?qsearchterm=oklo</a>
&nbsp;

Management

'Sam Altman Steps Down As Oklo Board Chair, Freeing Nuclear Startup To Work With More AI Companies' - CNBC

Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $1.04 by 0.96 percent. This is a 12.9 percent increase over earnings of $0.93 per share from the same period last year. The company reported quarterly sales of $125.39 million which beat the analyst consensus estimate of $122.66 million by 2.23 percent. This is a 3.07 percent increase over sales of $121.66 million the same period last year.

MCRI

Monarch Casino & Resort Q1 GAAP EPS $1.05 Beats $1.04 Estimate, Sales $125.39M Beat $122.66M Estimate

Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $0.49 by 212.24 percent. This is a 218.75 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $475.633 million which beat the analyst consensus estimate of $356.613 million by 33.38 percent. This is a 44.07 percent increase over sales of $330.147 million the same period last year.

Pegasystems Q1 2025 Adj. EPS $1.53 Beats $0.49 Estimate, Sales $475.633M Beat $356.613M Estimate

Press Releases

PS International Group Ltd. Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

PS International Group Ltd. Announces First Half 2024 Unaudited Financial Results

PSIG

Air T

Addentax Group

C.H. Robinson Worldwide, Inc. - Common Stock

C.H. Robinson Worldwide

Callan Jmb

Freightos

Expeditors International of Washington, Inc. Common Stock

Expeditors International

FedEx

BingEx Limited - American Depositary Shares

BingEx

Freight Technologies, Inc. - Ordinary Shares

Freight Technologies

Forward Air

Globavend Holdings

GXO Logistics

Hong Kong Pharma Digital Technology Holdings Limited - Ordinary shares

Hong Kong Pharma Digital

Hub Group

Jayud Global Logistics Limited - Class A Ordinary Shares

Jayud Global Logistics

New Century Logistics (BVI) Limited - Ordinary Shares

New Century Logistics

Radiant Logistics

Shengfeng Development Limited - Class A Ordinary Shares

Shengfeng Development

United Parcel Service

ZTO Express (Cayman) Inc. American Depositary Shares, each representing one Class A ordinary share.

Comments

PS International Group

PS International Group (PSIG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL